StÃ©phanie Reynard

List of Publications by Year
in descending order

19	789	567281 15	794594 19
papers	citations	h-index	g-index

19	19	19	1043
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys. Journal of Virology, 2009, 83, 5890-5903.	3.4	163
2	Lassa Virus Nucleoprotein Mutants Generated by Reverse Genetics Induce a Robust Type I Interferon Response in Human Dendritic Cells and Macrophages. Journal of Virology, 2011, 85, 12093-12097.	3.4	63
3	Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. JCI Insight, 2017, 2, e88864.	5.0	60
4	Human Dendritic Cells Infected with the Nonpathogenic Mopeia Virus Induce Stronger T-Cell Responses than Those Infected with Lassa Virus. Journal of Virology, 2011, 85, 8293-8306.	3.4	57
5	Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs. PLoS Pathogens, 2017, 13, e1006610.	4.7	56
6	Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nature Communications, 2018, 9, 4013.	12.8	54
7	Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Science Translational Medicine, 2019, 11, .	12.4	53
8	Exonuclease Domain of the Lassa Virus Nucleoprotein Is Critical To Avoid RIG-I Signaling and To Inhibit the Innate Immune Response. Journal of Virology, 2014, 88, 13923-13927.	3.4	49
9	A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. Journal of Virology, 2018, 92, .	3.4	43
10	Immune parameters and outcomes during Ebola virus disease. JCI Insight, 2019, 4, .	5.0	36
11	A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Science Translational Medicine, 2021, 13, .	12.4	34
12	Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells. PLoS Pathogens, 2018, 14, e1007430.	4.7	28
13	The Exonuclease Domain of Lassa Virus Nucleoprotein Is Involved in Antigen-Presenting-Cell-Mediated NK Cell Responses. Journal of Virology, 2014, 88, 13811-13820.	3.4	24
14	Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques. Communications Biology, 2021, 4, 27.	4.4	19
15	<scp>NK</scp> cells are strongly activated by <scp>L</scp>assa and <scp>M</scp>opeia virusâ€infected human macrophages in vitro but do not mediate virus suppression. European Journal of Immunology, 2012, 42, 1822-1832.	2.9	18
16	Production of CXC and CC Chemokines by Human Antigen-Presenting Cells in Response to Lassa Virus or Closely Related Immunogenic Viruses, and in Cynomolgus Monkeys with Lassa Fever. PLoS Neglected Tropical Diseases, 2014, 8, e2637.	3.0	13
17	Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus. Viruses, 2019, 11, 287.	3.3	8
18	Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. PLoS Neglected Tropical Diseases, 2021, 15, e0009300.	3.0	6

#	Article	IF	Citations
19	Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys. Virulence, 2022, 13, 654-669.	4.4	5